CRSPCRISPR Therapeutics AG

59.50USDMkt Cap: 5.75B $P/E:

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein…

Key Statistics

Company
Market Cap5.75B $
Enterprise Value4.17B $
Revenue (TTM)13.39M $
Gross Profit-213.48M $
Net Income (TTM)-581.60M $
Revenue/Share0.1410 USD
Last Price59.50 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCH0334081137
Valuation
P/E (Trailing)
P/E (Forward)-17.01
PEG
EV/EBITDA-8.13
EV/Revenue311.57
P/S429.60
P/B3.29
EPS (TTM)-4.71
EPS (Forward)-3.50
52W Range
58.9316% of range62.53
52W High62.53 USD
52W Low58.93 USD
Profitability
Gross Margin0.00%
Oper. Margin-1127.55%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-30.26%
ROA-25.67%
Growth
Revenue Growth1041.40%
Earnings Growth
Cash Flow & Leverage
Operating CF-345.01M $
CapEx (TTM)25.91M $
FCF Margin-1611.75%
FCF Yield-3.75%
Net Debt-1.58B $
Net Debt/EBITDA3.08
Balance Sheet
Debt/Equity0.11
Current Ratio17.85
Quick Ratio17.79
Book Value/Sh18.07 USD
Cash/Share24.45 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)87.56 USD
Upside (mean)+47.2%
Target Range44.00 USD291.00 USD
$44.00+47.2% to mean$291.00
# Analysts18
Ownership
Shares Out.96.69M
Float96.27M
Insiders5.89%
Institutions77.86%
Short Interest
Short Ratio11.2d
Short % Float22.28%
Short % Out.19.46%
Shares Short18.82M
Short (prev mo.)20.40M
Technical
SMA 5052.77 (+12.8%)
SMA 20053.08 (+12.1%)
Beta1.74
S&P 52W Chg19.18%
Avg Vol (30d)2.45M
Avg Vol (10d)1.62M
Technical Indicators
RSI (14)66.6
MACD1.7508
MACD Signal0.8651
MACD Hist.+0.8856
BB Upper60.23 USD
BB Middle52.62 USD
BB Lower45.01 USD
BB Width28.92%
ATR (14)2.692 USD
Vol Ratio (20d)1.62x